Dual Tracer 11C-Choline and FDG-PET in the Diagnosis of Biochemical Prostate Cancer Relapse After Radical Treatment

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Molecular Imaging and Biology

• Publication date

  2010-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s11307-009-0243-yPMID 19543774
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Evaluation of [18F]-choline PET/CT for staging and restaging of prostate cancer

  2008cited by this paper
• The role of imaging in the detection of prostate cancer local recurrence after radiation therapy and surgery

  2008cited by this paper
• The detection rate of [11C]Choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer

  2007cited by this paper
• [11C]choline PET/CT imaging in occult local relapse of prostate cancer after radical prostatectomy

  2007cited by this paper
• Evaluation of [11C]‐choline positron‐emission/computed tomography in patients with increasing prostate‐specific antigen levels after primary treatment for prostate cancer

  2007cited by this paper
• 18F‐choline and/or 11C‐acetate positron emission tomography: detection of residual or progressive subclinical disease at very low prostate‐specific antigen values (<1 ng/mL) after radical prostatectomy

  2007cited by this paper
• Positron Emission Tomography/Computed Tomography with F-18-fluorocholine for Restaging of Prostate Cancer Patients: Meaningful at PSA < 5 ng/ml?

  2005cited by this paper
• In vivo uptake of [11C]choline does not correlate with cell proliferation in human prostate cancer

  2005cited by this paper
• Suspected local recurrence after radical prostatectomy: endorectal coil MR imaging.

  2004cited by this paper
• Management of prostate‐specific antigen relapse in prostate cancer: A European consensus

  2004cited by this paper
• Prostate‐specific antigen: A review of the validation of the most commonly used cancer biomarker

  2004cited by this paper
• Endorectal MR imaging and MR spectroscopic imaging for locally recurrent prostate cancer after external beam radiation therapy: preliminary experience.

  2004cited by this paper
• Direct comparison of 18F-FDG and 11C-methionine PET in suspected recurrence of glioma: sensitivity, inter-observer variability and prognostic value

  2004cited by this paper
• Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy. Prostate-specific antigen.

  2003cited by this paper
• Value of [11C]choline-positron emission tomography for re-staging prostate cancer: a comparison with [18F]fluorodeoxyglucose-positron emission tomography.

  2003influential reference
• 11C-acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse.

  2003cited by this paper
• 11C-choline positron emission tomography for the evaluation after treatment of localized prostate cancer.

  2003cited by this paper
• Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy.

  2003cited by this paper
• Biochemical recurrence of prostate cancer.

  2003cited by this paper
• Combined 18F-FDG and 11C-methionine PET scans in patients with newly progressive metastatic prostate cancer.

  2002cited by this paper
• Determination of the prognostic value of [18F]fluorodeoxyglucose uptake by using positron emission tomography in patients with non-small cell lung cancer

  2002cited by this paper
• American Society for Therapeutic Radiology and Oncology

  2001cited by this paper
• Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point?

  2001cited by this paper
• Local recurrence after radical prostatectomy: correlation of US features with prostatic fossa biopsy findings.

  2001cited by this paper
• Prostate specific antigen only progression of prostate cancer.

  2000cited by this paper
• The positive yield of imaging studies in the evaluation of men with newly diagnosed prostate cancer: a population based analysis.

  2000cited by this paper
• 9:30-9:45. Preliminary Evaluation of F-18 Fluorocholine (FCH) as a PET Tumor Imaging Agent.

  2000cited by this paper
• Positron emission tomography with 18fluorine‐labelled deoxyglucose: utility in localized and advanced prostate cancer

  1999cited by this paper
• The significance of recurrent PSA after radical prostatectomy: benign versus malignant sources.

  1999cited by this paper
• Natural history of progression after PSA elevation following radical prostatectomy.

  1999cited by this paper
• Predictors for maximal outcome in patients undergoing salvage surgery for radio-recurrent prostate cancer.

  1998cited by this paper
• PET imaging of prostate cancer using carbon-11-choline.

  1998cited by this paper
• Treatment Options for Prostate Cancer: Part 1--Stage, Grade, PSA, and Changes in the 1990's

  1998cited by this paper
• Consensus statement: guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel.

  1997cited by this paper
• Consensus statement: Guidelines for PSA following radiation therapy

  1997cited by this paper
• Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases.

  1994cited by this paper
• Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening.

  1993cited by this paper
• FDG accumulation in tumor tissue.

  1993cited by this paper
• Florodeoxyglucose imaging: A method to assess the proliferative activity of human cancer in vivo. Comparison with DNA flow cytometry in head and neck tumors

  1988cited by this paper
• Fluorodeoxyglucose imaging: a method to assess the proliferative activity of human cancer in vivo. Comparison with DNA flow cytometry in head and neck tumors.

  1988cited by this paper

• A prospective, multi-centre trial of PSMA-PET compared to FDG-PET for staging of newly diagnosed high risk prostate cancer

  2025cites this paper
• Diagnostic value of dual-tracer PET/CT with [18F]FDG and PSMA ligands in prostate cancer: an updated systematic review

  2025cites this paper
• 18F-FDG PET Is Not Inferior to 68Ga-PSMA PET for Detecting Biochemical Recurrent Prostate Cancer with a High Gleason Score: A Head-to-Head Comparison Study

  2023cites this paper
• 18F-prostate specific membrane antigen positron emission tomography/computerized tomography for lymph node staging in medium/high risk prostate cancer: A systematic review and meta-analysis

  2023influential citation
• Metastasis-Directed Therapy for Metachronous Lung Metastases in Prostate Cancer

  2023cites this paper
• History of Research on Phospholipid Metabolism and Applications to the Detection, Diagnosis, and Treatment of Cancer

  2022cites this paper
• Dual-Tracer PET-Computed Tomography Imaging for Precision Radio-Molecular Theranostics of Prostate Cancer: A Futuristic Perspective.

  2022cites this paper
• Lipid Metabolism and Epigenetics Crosstalk in Prostate Cancer

  2022cites this paper
• The Continuum of Metastatic Prostate Cancer: Interpreting PSMA PET Findings in Recurrent Prostate Cancer

  2022cites this paper
• The Evolving Role of 18F-FDG PET/CT in Diagnosis and Prognosis Prediction in Progressive Prostate Cancer

  2021cites this paper
• Diagnostic value of 18F-FDG PET/CT in patients with biochemical recurrent prostate cancer and negative 68Ga-PSMA PET/CT

  2021cites this paper
• Use of 68Ga-PSMA-11 and 18F-FDG PET-CT Dual-Tracer to Differentiate Between Lymph Node Metastases and Ganglia

  2021cites this paper
• Imaging Biochemical Recurrence After Prostatectomy: Where Are We Headed?

  2020cites this paper
• Molecular Imaging of Prostate Cancer

  2020cites this paper
• PET Parametric Imaging: Past, Present, and Future

  2020cites this paper
• Salvage Pelvic Lymph Node Dissection and Current State of Imaging for Recurrent Prostate Cancer: Does a Standard Exist?

  2020cites this paper
• Standardization of acquisition protocols using PET/CT with 18F-Choline in prostate cancer

  2020cites this paper
• Targeted Metabolomics Analyses Reveal Specific Metabolic Alterations in High Grade Prostate Cancer Patients.

  2020cites this paper
• Prostate MRI Essentials: A Practical Guide for Radiologists

  2020cites this paper
• Standardization of acquisition protocols using PET/CT with 18F-Choline in prostate cancer.

  2020cites this paper
• Relación de las cinéticas del PSA en la detección de la recurrencia del cáncer de próstata post prostatectomía radical con la 18f-colina tomografía por emisión de positrones/tomografía computada [PET/TC colina (PETC)]

  2020cites this paper
• Metastatic Seeding Attacks Bone Marrow, Not Bone: Rectifying Ongoing Misconceptions.

  2019cites this paper
• Usefulness of 18F-fluorocoline PET/CT in prostate cancer patients with biochemical recurrence: Influence of PSA kinetics and hormone therapy.

  2019cites this paper
• A Systematic Review on the Role of Imaging in Early Recurrent Prostate Cancer.

  2019influential citation
• Comparison of PSMA-PET/CT, choline-PET/CT, NaF-PET/CT, MRI, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: a systematic review and meta-analysis

  2019cites this paper
• SyStematic Review Diagnostic accuracy of F 18 flucholine Pet/ct for preoperative lymph node staging in newly diagnosed prostate cancer patients; a systematic review and meta-analysis

  2019cites this paper
• Usefulness of 18F-fluorocoline PET/CT in prostate cancer patients with biochemical recurrence: Influence of PSA kinetics and hormone therapy

  2019cites this paper
• Zastosowanie różnych znaczników PET-CT w leczeniu i diagnostyce wznowy raka prostaty w oparciu o doniesienia zajazdowe z konferencji onkologicznej ASTRO 59 i przegląd literatury.

  2019cites this paper
• Positron emission tomography in prostate cancer: An update on state of the art

  2018influential citation
• The utility of PET-based imaging for prostate cancer biochemical recurrence: a systematic review and meta-analysis

  2018cites this paper
• Diagnostic Performance of 11C-choline PET/CT and FDG PET/CT in Prostate Cancer.

  2018influential citation
• Metabolic Vulnerabilities of Prostate Cancer: Diagnostic and Therapeutic Opportunities.

  2018cites this paper
• Evolution of Nuclear Medicine in the diagnosis and treatment of prostate cancer.

  2018cites this paper
• Tiny Obturator Node Metastasis from Prostate Cancer Not Shown by FDG-PET/CT, CT, or MRI Detected by 11C-Choline PET/CT

  2018cites this paper
• Prostate cancer-specific PET radiotracers: A review on the clinical utility in recurrent disease.

  2018cites this paper
• Clinical implications of PET/CT in prostate cancer management

  2018cites this paper
• The evaluation of a novel imaging-based complex diagnostic and therapeutic pathway intervention for men who fail radiotherapy for prostate cancer

  2018influential citation
• The Diagnostic Accuracy of 18F-FDG PET/CT in Prostate Cancer: A Systemic Review and Meta-analysis

  2018influential citation
• PET/MRI in Prostate Cancer

  2018cites this paper
• Innovations in imaging modalities for recurrent and metastatic prostate cancer: a systematic review.

  2018cites this paper
• Use of Ipilimumab in Patients Diagnosed with Metastatic Melanoma: Three-Year Experience in a Private Hospital in Mexico City

  2017cites this paper
• PET and PET/CT with radiolabeled choline in prostate cancer: a critical reappraisal of 20 years of clinical studies

  2017cites this paper
• The use of PET/CT in prostate cancer

  2017cites this paper
• Role of PET-CT with 18F-fluorocholine in biochemical recurrence after treatment of prostate cancer with curative intent.

  2017cites this paper
• Clinical Significance of 18F-Fluorodeoxyglucose Avid Prostate Gland Incidentalomas on Positron Emission Tomography/Computed Tomography

  2017cites this paper
• Imaging on nodal staging of prostate cancer.

  2017cites this paper
• Radiotracers Used in Nuclear Medicine for Prostate Cancer Diagnosis and Follow-Up

  2017cites this paper
• Radiotrazadores empleados en medicina nuclear para el diagnóstico y seguimiento del cáncer de próstata

  2017cites this paper
• Incidental detection of a well-differentiated rectal adenocarcinoma by [18F]-Fluorocholine PET/CT in a patient with biochemical relapse of a prostate cancer

  2017cites this paper
• Papel de la tomografía por emisión de positrones-tomografía computerizada con 18F-fluorocolina en la recidiva bioquímica tras tratamiento con intención curativa del cáncer de próstata

  2017cites this paper
• PET of Glucose Metabolism and Cellular Proliferation in Prostate Cancer

  2016cites this paper
• Index lesion characterization by 11C‐Choline PET/CT and Apparent Diffusion Coefficient parameters at 3 Tesla MRI in primary prostate carcinoma

  2016cites this paper
• PSMA PET and Radionuclide Therapy in Prostate Cancer.

  2016cites this paper
• – Prostate Cancer New Clinical Indications for 18 F / 11 C-choline , New Tracers for Positron Emission Tomography and a Promising Hybrid Device for Prostate Cancer Staging : A Systematic Review of the Literature

  2016influential citation
• Role of serial multiparametric magnetic resonance imaging in prostate cancer active surveillance.

  2016cites this paper
• Have we overcome choline PET/CT for early detection of prostate cancer recurrence?

  2016cites this paper
• New Clinical Indications for (18)F/(11)C-choline, New Tracers for Positron Emission Tomography and a Promising Hybrid Device for Prostate Cancer Staging: A Systematic Review of the Literature.

  2016influential citation
• Current Status of Lymph Node Imaging in Bladder and Prostate Cancer.

  2016cites this paper
• Role of Positron Emission Tomography (PET) in the Setting ofBiochemically Recurrent Prostate Cancer

  2016cites this paper
• Comparison of meta-analyses among elastosonography (ES) and positron emission tomography/computed tomography (PET/CT) imaging techniques in the application of prostate cancer diagnosis

  2016cites this paper
• 11C-Choline-Avid but 18F-FDG-Nonavid Prostate Cancer with Lymph Node Metastases on Positron Emission Tomography

  2016cites this paper
• PET Tracers Beyond FDG in Prostate Cancer.

  2016cites this paper
• Influence of Four Radiotracers in PET/CT on Diagnostic Accuracy for Prostate Cancer: A Bivariate Random-Effects Meta-Analysis

  2016cites this paper
• 11C-Choline PET/CT in the primary diagnosis of prostate cancer: impact on treatment planning.

  2015cites this paper
• [11C]Acetate positron emission tomography-computed tomography imaging of prostate cancer lymph-node metastases correlated with histopathological findings after extended lymphadenectomy

  2015cites this paper
• Erratum to: 18F-Fluorocholine PET/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamide

  2015cites this paper
• The ability of 18F-choline PET/CT to identify local recurrence of prostate cancer

  2015cites this paper
• 18F-Fluorocholine PET/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamide

  2015cites this paper
• Contemporary role of salvage lymphadenectomy in patients with recurrence following radical prostatectomy.

  2015cites this paper
• Imaging and evaluation of patients with high-risk prostate cancer

  2015cites this paper
• Clinical utility of 18F‐fluorocholine positron‐emission tomography/computed tomography (PET/CT) in biochemical relapse of prostate cancer after radical treatment: results of a multicentre study

  2015cites this paper
• Trigger pSA predicting recurrence from positive choline PET/CT with prostate cancer after initial treatment

  2015cites this paper
• PET/CT with 11C-choline for evaluation of prostate cancer patients with biochemical recurrence: meta-analysis and critical review of available data

  2015cites this paper
• La PET/TC con (11)C-Colina en el Cáncer de Próstata

  2015cites this paper
• This Provisional PDF corresponds to the article as it appeared upon acceptance. Fully formatted PDF and full text (HTML) versions will be made available soon. Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence

  2014cites this paper
• Imaging of Tumor Metabolism: PET with Other Metabolites

  2014cites this paper
• Clinical translation of molecular imaging agents used in PET studies of cancer.

  2014cites this paper
• Oligometastases in prostate cancer: restaging stage IV cancers and new radiotherapy options

  2014cites this paper
• Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence

  2014cites this paper
• Erratum: Oligometastases in prostate cancer: restaging stage IV cancers and new radiotherapy options

  2014cites this paper
• Imaging requirements for personalized medicine: the oncologists point of view.

  2014cites this paper
• [Detection of second tumors in 11C-choline PET/CT studies performed due to biochemical recurrence of prostate cancer].

  2014cites this paper
• [Detection of second tumors in 11C-choline PET/CT studies performed due to biochemical recurrence of prostate cancer].

  2014cites this paper
• Meta-analysis of 11C-choline and 18F-choline PET/CT for management of patients with prostate cancer

  2014cites this paper
• Comparison of choline-PET/CT, MRI, SPECT, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: a meta-analysis

  2014cites this paper
• FDG in Urologic Malignancies.

  2014cites this paper
• Update on positron emission tomography for imaging of prostate cancer

  2014cites this paper
• Functional and molecular imaging: applications for diagnosis and staging of localised prostate cancer.

  2013cites this paper
• Choline PET/CT for imaging prostate cancer: an update

  2013cites this paper
• Choline PET or PET/CT and Biochemical Relapse of Prostate Cancer: A Systematic Review and Meta-Analysis

  2013cites this paper
• ADJUVANT AND SALVAGE RADIOTHERAPY AFTER PROSTATECTOMY: ASTRO/AUA GUIDELINE

  2013cites this paper
• Comparative studies of radiolabeled choline positron emission tomography, histology of primary tumor and other imaging modalities in prostate cancer: a systematic review and meta-analysis

  2013cites this paper
• [Transanal endoscopic microsurgery for the treatment of a pararectal prostatic cancer recurrence].

  2013cites this paper
• 18F-Choline, 11C-choline and 11C-acetate PET/CT: comparative analysis for imaging prostate cancer patients

  2013cites this paper
• Imaging in prostate carcinoma.

  2013cites this paper
• Update on the use of radiopharmaceuticals for positron emission tomography imaging of prostate cancer

  2013cites this paper
• PET imaging in prostate cancer: focus on prostate-specific membrane antigen.

  2013cites this paper
• American Urological Association (AUA) Guideline ADJUVANT AND SALVAGE RADIOTHERAPY AFTER PROSTATECTOMY: ASTRO/AUA GUIDELINE

  2013cites this paper
• Empleo de la microcirugía transanal endoscópica en recidiva de cáncer de próstata a nivel pararrectal

  2013cites this paper
• Role of focal salvage ablative therapy in localised radiorecurrent prostate cancer

  2013cites this paper